Dow Jones 30 Stocks SEC Filings — June 09, 2026

09-06-2026

Novanta Inc. announced a definitive agreement to acquire Riverpoint Medical for $1.2 billion upfront plus a $250 million milestone payment in Q1 2027, expected to close in Q3 2026. The acquisition is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows, and is projected to double recurring medical consumables revenue to approximately $300 million. However, the upfront purchase price of $1.2 billion represents approximately 19x Riverpoint's estimated 2026 Adjusted EBITDA excluding synergies, indicating a high valuation multiple, and the transaction will increase Novanta's net leverage ratio to approximately 2.7x post-closing.

• · Riverpoint Medical will be reported under Novanta's Medical Solutions operating segment.
• · Novanta expects net leverage ratio of approximately 2.7x after closing, reducing to below 2.3x by year-end 2027.
• · Transaction financed through cash on hand, existing credit facility, and a $300 million equity raise.
• · Novanta confirms its previously issued Q2 and Full Year 2026 financial guidance for the standalone company and will update guidance post-close.
• · Conference call scheduled for June 9, 2026 at 8:30 a.m. ET.
• · Riverpoint has manufacturing operations in Portland, Oregon and San Jose, Costa Rica.

09-06-2026

CervoMed Inc. held its 2026 Annual Meeting on June 8, 2026, with 67.2% of outstanding shares represented. All eight director nominees were elected, and stockholders ratified RSM US LLP as auditor, approved advisory say-on-pay, and approved Amendment No. 1 to the 2025 Equity Incentive Plan. Notably, broker non-votes were high (3,033,573) on all director and compensation-related proposals, indicating significant abstention by brokers.

• · Record date for voting was April 17, 2026.
• · All eight director nominees were elected with votes ranging from 3,126,987 to 3,155,846 'For' and minimal 'Withheld' votes (29,174 to 58,033).
• · Ratification of RSM US LLP as auditor passed with 6,092,751 For, 21,433 Against, 104,409 Abstain.
• · Advisory say-on-pay passed with 3,073,013 For, 104,221 Against, 7,786 Abstain, plus 3,033,573 broker non-votes.
• · Approval of Amendment No. 1 to the 2025 Equity Incentive Plan passed with 3,044,744 For, 132,860 Against, 7,416 Abstain, plus 3,033,573 broker non-votes.
• · Broker non-votes were 3,033,573 on all proposals except the auditor ratification (which had no broker non-votes).

09-06-2026

AITX filed its audited FY2026 10-K, confirming revenue grew 26% YoY to $7.7M and gross margin expanded to 71% from 61%, while operating expenses remained flat. However, the company reported a loss from operations of $11.9M, an accumulated deficit of ~$165M, and only $144K cash on hand, with auditors issuing a going concern qualification. The company also detailed its three-pillar operating strategy (Stationary, Mobile, Agentic AI) and noted that its residential product line (RAD-R) generated immaterial revenue, substantially below expectations.

• · Auditors issued a going concern qualification due to recurring net losses, negative working capital, ~$165M accumulated deficit, and dependence on external financing.
• · Total liabilities of ~$58M exceed total assets of ~$9M, resulting in a stockholders' deficit of ~$49M.
• · Cash on hand was only ~$144K, insufficient to fund operations for any extended period without additional financing.
• · Approximately 96% of outstanding loans payable are owed to entities controlled by a single individual, creating concentration risk.
• · The residential product line (RAD-R) generated immaterial revenue in FY2026, substantially below expectations.
• · ROAMEO commenced commercial billing in May 2026 after ~$20M in cumulative development investment.
• · The company has experienced significant common share dilution, including issuances under an equity financing arrangement of up to $30M.
• · The company has not been profitable in any fiscal year of its operating history.
• · RAD-G (agentic AI platform) has not yet produced revenue commensurate with management's expectations.
• · The company serves customers including one Fortune Top 10 enterprise and several additional Fortune 500 enterprises.

09-06-2026

Inflection Point Acquisition Corp. VI (IPFX) filed a Form 425 with the SEC on June 9, 2026, in connection with its proposed business combination with Quantum Space, LLC. The filing includes social media communications from Quantum Space and its executives (Kam Ghaffarian, Jim Bridenstine, Kerry Wisnosky) promoting the merger, but contains no financial data or performance metrics. The filing is primarily a regulatory disclosure with extensive forward-looking statements and risk factors, highlighting that Quantum Space's flagship vehicle, Ranger, is still in development and has not been manufactured, operated, or sold to date.

• · Quantum Space's flagship vehicle, Ranger, is currently in development and has not been manufactured, operated, or sold to date.
• · Ranger is intended to have a refuelable and modular architecture with an operational life of up to 15 years.
• · The business combination requires shareholder approval and is subject to various closing conditions.
• · Inflection Point's final prospectus for its IPO was filed with the SEC on March 30, 2026 (File No. 333-292443).
• · The filing includes social media posts from Quantum Space and its executives on LinkedIn and X (formerly Twitter) dated June 8, 2026.

09-06-2026

On June 4, 2026, Qorvo's Compensation Committee approved FY2027 performance-based restricted stock unit (PBRSU) awards for named executive officers, with 50% tied to non-GAAP operating income, 25% to gross margin, and 25% to revenue objectives. The committee also granted a retention award to Philip J. Chesley comprising 9,618 service-based RSUs and 9,618 PBRSUs linked to organic HPA revenue growth. The awards reflect shareholder feedback from the 2025 say-on-pay vote, removing prior objectives-based metrics. The fair market value per share was set at $103.97.

• · The FY2027 PBRSUs use three performance metrics: non-GAAP operating income (50% weight), gross margin (25%), and revenue (25%).
• · The non-GAAP operating income and gross margin objectives are measured over three one-year periods (FY2027, FY2028, FY2029); the revenue objective is measured over a single one-year period (FY2029).
• · Each officer can earn up to 200% of target PBRSUs for each metric if objectives are fully met.
• · The Retention Award for Mr. Chesley includes 9,618 service-based RSUs vesting in two equal annual installments and 9,618 PBRSUs tied to organic HPA revenue growth over FY2027 and FY2028.
• · The Retention Award PBRSUs have a maximum payout of 100% of target (not 200%).
• · The Retention Award RSUs (but not PBRSUs) will fully vest upon a qualifying termination in connection with a change in control.
• · Upon the closing of the merger with Skyworks, the Retention Award PBRSUs will remain in place and eligible to be earned post-closing, not measured at closing.
• · The fair market value per share for both awards was $103.97, based on the June 4, 2026 closing price.
• · The awards were approved in response to shareholder feedback from the 2025 say-on-pay vote, removing prior objectives-based metrics.

09-06-2026

Cantor Equity Partners VII, Inc. filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 25,000,000 Class A ordinary shares at $10.00 per share, aiming to raise $250,000,000. The blank check company has not yet selected a business combination target and must complete an initial business combination within 24 months of the offering closing or liquidate. The sponsor purchased 7,187,500 founder shares for $25,000 (approximately $0.003 per share), resulting in immediate and substantial dilution for public shareholders, and has agreed to a private placement of 600,000 Class A shares at $10.00 per share ($6,000,000 aggregate).

• · The company is a blank check company (SPAC) incorporated in the Cayman Islands with SIC code 6770.
• · The underwriters have a 45-day option to purchase up to an additional 3,750,000 Class A ordinary shares to cover over-allotments.
• · Unlike some other SPAC IPOs, this offering does not include warrants for investors.
• · The sponsor note of up to $4,312,500 will not bear interest and is convertible into Class A shares at $10.00 per share no earlier than 60 days after the offering date.
• · If the company fails to complete a business combination within 24 months, it will redeem 100% of public shares from the trust account.
• · Public shareholders have redemption rights upon completion of a business combination, but those holding more than 15% of public shares may be restricted from redeeming without prior consent if a shareholder vote is held.
• · The founder shares (Class B) automatically convert into non-redeemable Class A shares upon consummation of the initial business combination.
• · The company has not initiated any discussions with any business combination target.

09-06-2026

Brilliant N.E.V. Corp. filed an 8-K on June 9, 2026, covering Items 5.01 (Change in Control), 5.02 (Departure of Directors or Principal Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing indicates significant corporate governance changes, including a change in control and officer/director departures, but no specific financial figures or period-over-period comparisons were provided in the filing metadata.

• · The company was formerly known as Clancy Corp (filings through 2023-08-09).
• · The company's SIC code is 2840 (Soap, Detergent, Cleaning Preparations, Perfumes, Cosmetics).
• · Fiscal year ends July 31.
• · The filing includes items related to changes in control, officer/director changes, and amendments to governing documents.

09-06-2026

Starton Holdings, Inc. filed Amendment No. 4 to its S-1 registration statement for an initial public offering of 5,000,000 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The company is a clinical-stage biotechnology firm focused on improving cancer therapies via proprietary delivery technology. The offering includes a 45-day underwriter option for an additional 750,000 shares, and the company has applied to list on Nasdaq under the symbol 'STA'.

• · The company is a clinical-stage biotechnology company focused on improving standard-of-care therapies for cancer through proprietary delivery technology systems.
• · The company has applied to list its common stock on the Nasdaq Capital Market under the symbol 'STA'.
• · The estimated initial public offering price per share is between $5.00 and $7.00.
• · The underwriters have a 45-day option to purchase up to an additional 750,000 shares to cover over-allotments.
• · The company is an 'emerging growth company' and a 'smaller reporting company' under federal securities laws.
• · The company's principal executive offices are located at 215 College Road, Suite 300, Paramus, NJ 07652.

09-06-2026

Lionheart Holdings appointed Freddy J. Martinez (age 70) as a Class III director effective June 6, 2026, filling a new board vacancy. The appointment reflects the Company's strategic shift to focus on oil and gas opportunities in Venezuela. Mr. Martinez brings over 40 years of investment management and energy sector experience, with no cash compensation paid for his services.

• · Mr. Martinez is independent under NASDAQ rules and serves as President/CEO of Forem Investments LLC, a registered investment adviser founded in December 2013.
• · He holds an MBA in finance from Wharton, an M.S. in Engineering from the Moore School, and a B.S. in Mechanical Engineering from Universidad Simón Bolívar.
• · The Company's definitive proxy statement for an extension of time through March 20, 2027 was mailed to shareholders of record as of May 15, 2026; a special meeting is scheduled for June 15, 2026.
• · Mr. Martinez has not received any cash compensation; he entered into a standard director indemnification agreement and the Letter Agreement dated June 17, 2024.

09-06-2026

XOMA Royalty Corp filed an S-4/A registration statement detailing its proposed merger with a subsidiary of Ligand Pharmaceuticals Incorporated. The merger, expected to close in Q3 2026, will result in XOMA Royalty stockholders receiving cash and CVRs, with dissenter's rights available under Nevada law. XOMA Royalty reported total cash receipts of $50.5 million in 2025, comprising $33.6 million in commercial payments and $16.9 million in milestone payments and other fees, though the filing did not provide comparable prior-period data for context. Risks include a $40.0 million termination fee under certain conditions if the merger is not completed.

• · Special Meeting to vote on proposals scheduled for July 13, 2026, at 9:00 a.m. PT via virtual meeting.
• · Record date for the Special Meeting is June 5, 2026.
• · Approval of Merger Agreement Proposal requires affirmative vote of holders of a majority of outstanding voting power; abstentions and broker non-votes count against.
• · Holding Company Reorganization Proposal approval is conditioned on Merger Agreement Proposal approval.
• · Merger is taxable for U.S. federal income tax purposes; tax treatment of CVRs is uncertain.
• · Closing conditions include stockholder approval, no adverse government action, expiration of HSR Act waiting period, and completion of Holding Company Reorganization.
• · If merger is not completed, XOMA Royalty remains an independent public company and its common stock continues trading on Nasdaq.

09-06-2026

Enveric Biosciences, Inc. filed an 8-K on June 8, 2026, announcing the release of its Q2 2026 Investor Presentation, which management intends to use in discussions with investors, analysts, and other stakeholders. The presentation is furnished under Regulation FD and is available on the company's website. No specific financial figures or performance data were disclosed in the filing itself.

• · The Investor Presentation is furnished as Exhibit 99.1 and incorporated by reference into the 8-K.
• · The presentation is available on the company's website at https://www.enveric.com/investors/events/.
• · The information in this 8-K is not deemed 'filed' for purposes of Section 18 of the Exchange Act and is not incorporated by reference into any SEC filings unless expressly set forth.

09-06-2026

GSK plc announced a definitive agreement to acquire Nuvalent, Inc. for $10.6 billion ($124 per share in cash), representing a 40% premium to the last closing price. The deal includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung cancer currently under FDA review with target decision dates in September and November 2026, plus a phase I HER2 inhibitor (NVL-330). The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, but will cause low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028.

• · The transaction is expected to close in Q3 2026, subject to tender of a majority of Nuvalent's Class A shares and HSR Act clearance.
• · GSK will assume Nuvalent's existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield.
• · The acquisition will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating.
• · GSK reaffirmed its 2026 dividend of 70p and progressive dividend policy.
• · GSK's FY 2026 guidance of 7-9% core operating profit and core EPS growth remains unchanged.
• · GSK expects low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028 from the transaction.
• · The acquisition is expected to be accretive to core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation.
• · Zidesamtinib has a target FDA decision date of 18 September 2026; neladalkib has a target decision date of 27 November 2026.
• · Both zidesamtinib and neladalkib have received FDA Breakthrough Therapy and Orphan Drug Designations.
• · The deal includes Nuvalent's preclinical portfolio of multiple programmes.

09-06-2026

MultiSensor AI Holdings, Inc. filed a DEFA14A supplement to its proxy statement to correct a clerical error in the number of shares of common stock issued, outstanding, and entitled to vote as of the record date for the June 12, 2026 annual meeting. The corrected figure is 2,019,434 shares, up from the previously reported 2,012,293 shares. The supplement does not modify any other information in the proxy statement.

• · The correction was due to a clerical error in the original proxy statement filed on April 24, 2026.
• · The supplement was filed on June 9, 2026, three days before the annual meeting scheduled for June 12, 2026.
• · Stockholders who have already submitted a proxy do not need to take action unless they wish to change their vote.
• · The corrected proxy materials are available at www.cstproxy.com./multisensorai/2026 and on the SEC's website.

09-06-2026

DraftKings Inc. announced preliminary operating metrics for May 2026, showing strong month-over-month growth in its Predictions offering. Annualized consumer volume increased 24% MoM to $1.3 billion, and annualized total volume traded rose 34% MoM to $3.1 billion, compared to April 2026. The data is preliminary and unaudited, with no prior period comparisons or negative metrics disclosed.

• · The operating metrics are preliminary, unaudited, and based on currently available internal data, subject to adjustment.
• · The filing is under Item 7.01 Regulation FD Disclosure and is furnished, not filed, for SEC purposes.
• · No prior period (April 2026) absolute values were disclosed, only percentage changes.

09-06-2026

Soluna Holdings reported Q1 2026 revenue up 58% YoY, with Bitcoin hosting revenue up 178% YoY and a record hash rate, marking the fourth consecutive quarter of growth. However, the company also disclosed ongoing construction and development risks, including transformer repairs at Project Dorothy 1A that were completed in May, and noted that Project Kati 1B construction is still ongoing with Phase 3 ahead of schedule. The company regained Nasdaq compliance and signed a definitive JV agreement for Kati 2, but tenant due diligence and commercial negotiations remain in early stages.

• · Soluna regained compliance with Nasdaq listing requirements.
• · A definitive joint venture agreement was signed with Metrobloks for Kati 2, replacing the prior non-binding MOU.
• · A definitive purchase agreement was signed for 300 acres for Dorothy 3.
• · Briscoe Wind Farm (150 MW) was successfully integrated into operations.
• · Project Kati 1B Phase 1 (12 MW) achieved substantial completion; Phase 2 (9 MW) achieved mechanical and power commissioning; Phase 3 (14 MW) is ahead of schedule.
• · Project Annie (74 MW) is being developed for a potential new customer; ERCOT interconnection studies are nearing completion.
• · Tenant due diligence continues with Hyperscalers and Neoclouds; formal commercial negotiations started with at least one potential tenant for Kati 2.
• · The company engaged a top-tier investment bank to lead capital raising for Kati 2.
• · Transformer repair work at D1A was completed in May, returning operations to full capacity.

09-06-2026

Apollo Global Management held its 2026 Annual Meeting on June 8, 2026, where all 13 director nominees were elected, and stockholders approved, on an advisory basis, the compensation of named executive officers (say-on-pay) with 321,612,541 votes for and 131,990,818 against. Stockholders also voted in favor of holding say-on-pay votes every one year (274,693,342 votes for one year vs. 178,315,278 for three years), and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026.

• · All 13 director nominees were elected with 'for' votes ranging from 439,445,869 (Marc Beilinson) to 451,938,638 (James Belardi).
• · Broker non-votes totaled 56,075,043 to 56,075,061 across proposals.
• · Say-on-pay approval received 321,612,541 votes for and 131,990,818 against, with 166,571 abstentions.
• · Say-on-frequency vote: 274,693,342 for one year, 521,879 for two years, 178,315,278 for three years, 239,430 abstentions.
• · Ratification of Deloitte & Touche LLP: 505,479,171 for, 4,283,213 against, 82,606 abstentions.

09-06-2026

Verde Clean Fuels, Inc. filed a DEFA14A supplement to its definitive proxy statement for the 2026 Annual Meeting of Stockholders, disclosing that director Martijn Dekker resigned from the Board effective June 3, 2026. The Board now consists of seven members, and Mr. Dekker did not serve on any Board committees. All other information in the original proxy statement remains unchanged.

• · The resignation was effective June 3, 2026, and Mr. Dekker informed the Board on the same date.
• · Mr. Dekker did not serve on any Board committee.
• · The Annual Meeting remains scheduled for June 12, 2026 at 10:00 a.m. ET.

09-06-2026

Texas Ventures Acquisition IV Corp filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 15,000,000 units at $10.00 per unit, each consisting of one Class A ordinary share and one-half of one redeemable warrant, aiming to raise $150,000,000. The company is a blank check company targeting a business combination in any industry, with no target selected yet. However, the filing highlights substantial dilution to public shareholders due to the sponsor's nominal purchase price of founder shares ($0.004 per share) and potential conflicts of interest, as the sponsor and underwriters are also purchasing private placement warrants for $5,650,000.

• · The company has not selected any business combination target and no substantive discussions have been initiated.
• · Each whole warrant entitles holder to purchase one Class A ordinary share at $11.50 per share, exercisable 30 days after business combination and expiring 5 years after.
• · Public shareholders have redemption rights upon business combination at per-share price equal to trust account amount divided by outstanding public shares, but shareholders holding more than 15% of shares sold in offering are restricted from redeeming without prior consent.
• · Founder shares were purchased at approximately $0.004 per share, resulting in immediate and substantial dilution for public shareholders.
• · Up to $300,000 in loans from sponsor will be repaid after offering, and sponsor will receive $10,000 per month for services.
• · Up to $1,500,000 of working capital loans may be convertible into warrants at $1.00 per warrant.
• · Prior to business combination, payments to sponsor/officers for finder's, advisory, consulting, or success fees may be made from funds outside the trust account, creating potential conflicts of interest.

09-06-2026

BARK, Inc. reported its financial results for the fiscal year ended March 31, 2026. Concurrently, the Board of Directors authorized a $40.0 million stock repurchase program to be funded by ongoing free cash flow. The filing does not disclose the specific financial performance metrics, so directionality (improvement or decline) cannot be determined.

• · The stock repurchase program is not subject to a termination or expiration date.
• · Repurchases may be made in open market transactions under Rule 10b-18 and/or Rule 10b5-1, privately negotiated transactions, or by other means.
• · The program does not obligate the Company to acquire any specific number of shares.

09-06-2026

VerifyMe, Inc. (VRME) filed a Form 425 on June 9, 2026, disclosing a second amendment to its merger agreement with Open World Ltd., revising the definition of Fully Diluted Company Shares to include shares issuable under existing equity agreements. The amendment was entered into on June 4, 2026, and the merger is structured as a reverse triangular merger where VRME Subsidiary Corp. will merge into Open World, making Open World a wholly-owned subsidiary of VerifyMe.

• · The second amendment was dated June 4, 2026, and filed as Exhibit 2.1 to the Form 8-K.
• · The amendment revises the definition of 'Fully Diluted Company Shares' to include Open World ordinary shares issuable under existing agreements to issue Equity Interests.
• · The merger is structured as a reverse triangular merger: Merger Sub will merge into Open World, Merger Sub will cease to exist, and Open World will become a wholly-owned subsidiary of VerifyMe.
• · The filing references a prior Registration Statement on Form S-4/A filed on June 8, 2026, which incorporates the amendment.

09-06-2026

Klaviyo held its 2026 annual meeting on June 9, 2026, where stockholders elected three Class III directors (Jennifer Ceran, Chano Fernández, and Susan St. Ledger) and approved, on a non-binding advisory basis, the compensation of named executive officers. The appointment of Deloitte & Touche LLP as independent auditor for fiscal year 2026 was also ratified. All proposals passed with overwhelming support, with director votes ranging from 1.491 billion to 1.510 billion votes 'for' and minimal opposition.

• · The annual meeting was held virtually via live audio webcast.
• · All three director nominees were elected to hold office until the 2029 annual meeting.
• · Executive compensation was approved on a non-binding advisory basis with 1.494 billion votes for and 18.3 million against.
• · Ratification of Deloitte & Touche LLP as auditor for fiscal year ending December 31, 2026 passed with 1.537 billion votes for and only 428,789 against.
• · No other matters were submitted to or voted on at the meeting.

09-06-2026

Duluth Holdings Inc. reported a net loss of $10.1M for Q1 FY26, an improvement from the $15.3M loss in Q1 FY25, driven by a 6.1% increase in gross profit and lower SG&A expenses. However, net sales declined 4.0% to $98.6M, and the company recorded $2.7M in asset impairment and $1.4M in restructuring charges. Cash and cash equivalents fell sharply to $6.1M from $16.3M at year-end, and the company drew $6.0M on its line of credit.

• · Net loss per share improved to $(0.29) from $(0.45) in the prior year quarter.
• · Interest expense decreased to $0.8M from $1.5M YoY.
• · Net cash used in operating activities improved to $(13.4M) from $(56.5M) YoY, primarily due to lower inventory build and reduced trade payables outflow.
• · The company drew $6.0M on its line of credit during Q1, compared to no balance at year-end.
• · Inventory remained essentially flat at $132.4M vs $131.3M at year-end.
• · Impairment of long-lived assets increased to $2.7M from $0.5M YoY.
• · Restructuring expense of $1.4M was recorded in Q1 FY26 with no comparable charge in the prior year.
• · Total shareholders' equity declined to $156.6M from $166.1M at year-end, driven by the net loss and treasury stock repurchases.

09-06-2026

Invesco Ltd. filed an 8-K on June 9, 2026, disclosing preliminary assets under management (AUM) for May 2026 via a press release. The filing is a routine monthly update under Regulation FD, providing investors with early visibility into the firm's AUM trends.

• · The press release is dated June 9, 2026, and covers preliminary AUM for the month ended May 31, 2026.
• · The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• · The exhibit attached is Exhibit 99.1, which contains the full press release.

09-06-2026

Cracker Barrel reported Q3 FY2026 revenue of $797.4M, down 2.9% YoY, with GAAP EPS of $1.90 (boosted by a $47.4M litigation settlement) but adjusted EPS of only $0.29, down 50% from $0.58 a year ago. Adjusted EBITDA fell 16.2% to $40.3M from $48.1M, though the company raised its full-year revenue guidance to $3.27B-$3.30B and adjusted EBITDA guidance to $120M-$125M (from $85M-$100M). Comparable store restaurant sales declined 2.6% and retail sales fell 1.8%, while operating income plunged 55% to $6.7M.

• · GAAP net income of $42.8M includes a $47.4M benefit from interchange fee litigation settlement; without it, adjusted net income was only $6.5M.
• · Total debt of $486.6M consists of $149.9M short-term (0.625% Convertible Notes due June 2026) and $336.8M long-term (1.75% Convertible Notes due 2030); no borrowings on credit facility.
• · Company intends to repay the $149.9M short-term debt by drawing on its $541.3M available credit facility.
• · Board declared a quarterly dividend of $0.25 per share, payable August 12, 2026 to holders of record July 17, 2026.
• · FY2026 guidance raised: revenue $3.27B-$3.30B (from $3.24B-$3.27B), adjusted EBITDA $120M-$125M (from $85M-$100M).
• · Commodity inflation guidance lowered to low 2% range (from 2.0%-2.5%); hourly wage inflation guidance lowered to low 2% range (from 2.5%-3.0%).
• · Capital expenditures unchanged at $105M-$115M; 2 new stores opened (no change).
• · Nine-month FY2026 total revenue declined 6% YoY to $2.469B; GAAP net income fell 51% to $19.5M; operating loss of $25.6M vs. income of $51.1M in prior year period.

09-06-2026

Gloo Holdings reported total revenue of $41.5M for the quarter ended April 30, 2026, a significant increase of 237.6% from $12.3M in the prior-year quarter, driven by strong growth in both Platform revenue ($24.1M vs $8.5M) and Platform Solutions revenue ($17.4M vs $3.8M). However, the company reported a net loss of $17.1M, an improvement from a $27.0M loss in Q1 2025, but operating expenses grew 75.3% to $60.3M, outpacing revenue growth. Cash and cash equivalents decreased sharply to $33.0M from $57.3M at the start of the period, and the accumulated deficit widened to $56.9M from $40.1M.

• · Pro forma revenue for Q1 2025 was $34.2M, compared to actual $12.3M, indicating the impact of acquisitions.
• · Pro forma net loss for Q1 2025 was $26.2M, compared to actual $27.0M.
• · Interest expense decreased significantly to $0.98M in Q1 2026 from $2.75M in Q1 2025.
• · The company had a gain from change in fair value of financial instruments of $0.75M in Q1 2026, compared to a loss of $3.19M in Q1 2025.
• · Equity-based compensation expense increased to $3.75M in Q1 2026 from $2.18M in Q1 2025.
• · Total liabilities decreased to $94.6M as of Apr 30, 2026 from $106.0M as of Jan 31, 2026.
• · Current debt increased to $17.8M from $5.8M, while non-current debt decreased to $16.0M from $29.5M.
• · Goodwill remained relatively flat at $107.3M.
• · Net cash used in operating activities improved to $17.1M from $21.2M in the prior year quarter.

09-06-2026

Payoneer Global Inc. held its annual meeting on June 9, 2026, where stockholders elected three Class II directors, ratified the appointment of Kesselman & Kesselman (PwC) as independent auditor for fiscal 2026, and approved named executive officer compensation on a non-binding advisory basis. All proposals passed with strong shareholder support, though director Amir Goldman received a notable 15.9 million against votes (7.9% of votes cast).

• · Director Amir Goldman received 15,938,308 against votes (7.9% of votes cast), the highest opposition among the three director nominees.
• · Auditor ratification received 5,300,100 abstentions, the highest abstention count among all proposals.
• · Say-on-pay had 16,478,407 against votes (8.2% of votes cast excluding broker non-votes), indicating some shareholder dissent on executive compensation.
• · All director elections and say-on-pay had 66,992,499 broker non-votes, representing about 25% of total outstanding shares (based on auditor ratification total votes).

09-06-2026

Hooker Furnishings Corporation filed an 8-K on June 9, 2026, to announce a press release issued the same day, which is attached as Exhibit 99.1. The filing does not disclose any financial results, strategic changes, or material events beyond the press release reference.

• · The 8-K was filed under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
• · Exhibit 99.1 is the press release dated June 9, 2026, but its content is not summarized in the filing.
• · No financial data, transactional details, or operational metrics were provided in the filing.

09-06-2026

Fifth Third Bancorp filed an 8-K on June 9, 2026, announcing that it will present at the Morgan Stanley US Financials Conference on June 10, 2026. The filing includes a copy of the presentation as Exhibit 99.1, which is furnished under Regulation FD and not deemed filed for SEC purposes.

• · The presentation will be given at the Morgan Stanley US Financials Conference on June 10, 2026.
• · The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• · The information is furnished, not filed, and is not incorporated by reference into any SEC filing unless expressly stated.

09-06-2026

Adaptive Biotechnologies held its 2026 annual meeting on June 5, 2026, where shareholders voted on three proposals: election of two Class I directors, an advisory vote on 2025 executive compensation, and ratification of Ernst & Young as independent auditor. All proposals passed with strong support, though director Robert Hershberg received a notable 28.19% withhold/abstain vote, indicating some shareholder dissent.

• · The annual meeting was held on June 5, 2026, with a quorum present.
• · Proposal 1: Robert Hershberg received 93,188,652 votes for (71.81%) and 36,573,708 withhold/abstain (28.19%).
• · Proposal 1: Katey Owen received 126,803,695 votes for (97.72%) and 2,958,666 withhold/abstain (2.28%).
• · Proposal 2: Advisory vote on 2025 executive compensation received 125,287,618 for (96.55%), 4,316,144 against (3.33%), and 158,599 abstain (0.12%).
• · Proposal 3: Ratification of Ernst & Young received 142,609,643 for (99.50%), 484,798 against (0.34%), and 238,779 abstain (0.17%).
• · Broker non-votes were 13,570,859 for Proposals 1 and 2, and zero for Proposal 3.

09-06-2026

Revolve Group held its 2026 Annual Meeting on June 5, 2026, where stockholders elected all five director nominees, ratified KPMG as independent auditor for FY2026, and approved executive compensation on an advisory basis. All proposals passed with overwhelming support, with director votes ranging from 313.3 million to 336.5 million votes for, and broker non-votes totaling 1.68 million on director and compensation proposals.

• · The annual meeting was held on June 5, 2026, and the proxy statement was filed on April 24, 2026.
• · All five director nominees were elected to serve until the 2027 annual meeting.
• · KPMG LLP was ratified as independent auditor for the fiscal year ending December 31, 2026.
• · The advisory vote on executive compensation was non-binding and passed with 336,186,150 votes for.
• · Broker non-votes were 1,684,428 on director elections and the compensation proposal, but zero on auditor ratification.

09-06-2026

Interactive Strength Inc. (TRNR) held its 2026 annual meeting on June 8, 2026, where stockholders approved all eight proposals, including the election of Class III directors, ratification of Deloitte & Touche as auditor, and the issuance of shares related to the Wattbike and Ergatta acquisitions. However, several proposals received significant opposition, with the reverse stock split proposal (Proposal Six) showing 294,645 votes against and 86,118 abstentions, and the 2023 Stock Incentive Plan amendment (Proposal Five) had 90,336 votes against, indicating notable shareholder dissent.

• · Proposal Six (reverse stock split) had 294,645 votes against and 86,118 abstentions, the highest opposition among all proposals.
• · Proposal Five (amendment to 2023 Stock Incentive Plan) received 90,336 votes against, the second-highest opposition.
• · Proposal Eight (advisory vote on frequency of future NEO compensation votes) resulted in 121,166 votes for three years, 66,030 for one year, and 118,575 abstentions.
• · All proposals passed despite significant broker non-votes of 601,515 shares on most proposals (except Proposals Two and Six).
• · Proposal Two (ratification of auditor) had no broker non-votes and was approved with 883,747 votes for.

09-06-2026

Regenerative Medical Technology Group Inc. (RMTG) reported Q1 2026 revenue of $2.64M, up 93.5% YoY from $1.36M, driven by strong growth in training and product supplies. However, net loss widened to $876k from $760k due to higher interest expense and operating costs. The company's accumulated deficit reached $76.2M, and total liabilities exceeded assets, resulting in a stockholders' deficit of $35.6M.

• · Revenue breakdown for Q1 2026: Training $772k, Product supplies $1.27M, Patient procedures $600k.
• · Segment reporting: Global Stem Cells Group generated all revenue ($2.64M) and net profit of $172k, while Regenerative Medical Technology Group had no revenue and net loss of $1.05M.
• · Non-cash adjustments: Amortization of debt discount $730k, change in fair value of derivative liability gain $1.08M.
• · Cash flow: Operating activities provided $102k, investing used $315k (property and equipment), financing provided $318k (debt issuance).
• · Total current liabilities $38.2M vs current assets $1.57M, indicating significant liquidity risk.
• · Accrued interest of $18.0M as of March 31, 2026, up from $16.6M at year-end 2025.
• · Derivative liability decreased from $2.41M to $1.32M due to fair value change.
• · No cash paid for interest or income taxes during Q1 2026.

09-06-2026

Innovative Industrial Properties, Inc. held its 2026 annual meeting on June 9, 2026, where stockholders approved the 2026 Omnibus Incentive Plan, replacing the 2016 plan, and ratified BDO USA as auditor. All five director nominees were elected, but Scott Shoemaker received significant withheld votes (6,595,430 vs. 10,281,923 for), and the advisory vote on executive compensation passed with only 10,666,254 for vs. 6,025,986 against, indicating notable shareholder dissent.

• · The 2026 Plan replaces the Prior Plan, which was terminated as of June 9, 2026, but continues to govern outstanding awards.
• · Proposal 3 (2026 Plan) received 13,306,826 votes for, 3,466,132 against, and 104,395 abstentions, with 4,992,391 broker non-votes.
• · Proposal 4 (advisory vote on executive compensation) received 10,666,254 for, 6,025,986 against, and 185,113 abstentions.
• · Proposal 5 (frequency of future advisory votes) favored 'One Year' with 16,097,437 votes.
• · Director Scott Shoemaker had 6,595,430 votes withheld, the highest among nominees.
• · Ratification of BDO USA passed with 21,610,111 for, 179,893 against, and 79,740 abstentions.

09-06-2026

Axe Compute Inc. filed an 8-K on June 9, 2026, to disclose updated risk factors related to its expansion into GPU computing infrastructure for data centers. The filing supplements and updates risk factors from the 2025 Form 10-K, with the new risk factors superseding any inconsistent prior disclosures. No financial results or material operational metrics were reported in this filing.

• · The filing is a risk factor update, not a financial or operational results announcement.
• · The updated risk factors are incorporated by reference from Exhibit 99.1.
• · The filing is considered 'filed' for Section 18 of the Exchange Act purposes.

09-06-2026

Enovix Corp filed a DEFA14A additional proxy soliciting material on June 9, 2026, cautioning that forward-looking statements in the document speak only as of the date made and that the company undertakes no obligation to update them. The filing does not contain any new financial results, operational metrics, or material corporate events.

• · Filing is a DEFA14A (additional proxy materials) related to the annual meeting or special meeting proxy statement.
• · The document references forward-looking statements and disclaims any obligation to update them.
• · No financial figures, operational updates, or material events are disclosed in this filing.

09-06-2026

Vireo Growth Inc. dismissed Davidson & Company LLP as its independent auditor and appointed BDO USA, P.C. as its new independent registered public accounting firm, effective June 5, 2026. The change was approved by the Audit Committee and Board of Directors, with no disagreements or reportable events during the relevant periods. The company issued a press release on June 9, 2026, announcing the auditor change.

• · Davidson's reports for fiscal years ended December 31, 2025 and 2024 contained no adverse opinion or disclaimer of opinion and were not qualified or modified.
• · No disagreements or reportable events occurred between the company and Davidson during fiscal years 2024, 2025, and the interim period through June 5, 2026.
• · The company did not consult BDO regarding any accounting principles, audit opinions, or matters that would have been subject to a disagreement or reportable event.
• · The auditor change is effective for the fiscal year ending December 31, 2026.

09-06-2026

Urban Outfitters Inc. reported net sales of $1.48B for Q1 FY27 (three months ended April 30, 2026), up 11.4% from $1.33B in the prior-year quarter. Net income rose 6.8% to $115.7M from $108.3M, with diluted EPS increasing to $1.30 from $1.16. However, operating cash flow declined sharply to $15.5M from $33.0M, and the company reduced its share count by 4.97 million shares through aggressive repurchases, while total assets decreased 4.8% from January 31, 2026.

• · Gross profit margin was 36.6% in Q1 FY27 vs 36.8% in Q1 FY26, a slight decline.
• · SG&A expenses increased 11.7% to $402.9M from $360.8M, outpacing sales growth.
• · Capital expenditures surged 318.6% to $193.2M from $46.2M, primarily for property and equipment.
• · Inventory rose 9.5% to $726.9M from $663.8M a year ago.
• · Accumulated other comprehensive loss widened to $(26.4M) from $(22.1M) at January 31, 2026.
• · The company had no additional paid-in capital as of April 30, 2026, compared to $19.9M at January 31, 2026, due to share repurchases.

09-06-2026

At Lovesac's 2026 Annual Meeting on June 9, 2026, all eight director nominees were elected, and both Proposal 2 (advisory approval of fiscal 2026 executive compensation) and Proposal 3 (ratification of Deloitte & Touche as independent auditor) were approved. However, Proposal 2 received significant opposition, with 2,563,546 votes against (27.5% of votes cast), indicating notable shareholder dissent on executive pay.

• · Broker non-votes totaled 1,922,827 for all director elections and Proposal 2, but zero for Proposal 3 (auditor ratification).
• · Andrew Heyer received the lowest support among directors with 6,937,893 votes for and 2,387,687 withheld (25.6% withheld).
• · Proposal 3 (auditor ratification) passed overwhelmingly with 11,204,442 votes for, only 36,480 against, and 7,485 abstentions.

09-06-2026

Vistagen Therapeutics announced that its clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures recommended under ICH E1, an international regulatory standard for safety databases in drugs intended for long-term treatment of non-life-threatening conditions. This milestone supports the safety database for the program. No financial results or period-over-period comparisons were provided in this filing.

• · The press release was issued on June 9, 2026.
• · The ICH E1 standard governs safety database exposure recommendations for drugs intended for long-term treatment of non-life-threatening conditions.
• · The filing is a Form 8-K with items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• · The company is headquartered in South San Francisco, California.
• · The common stock trades on the Nasdaq Capital Market under the symbol VTGN.

09-06-2026

Live Oak Acquisition Corp. V entered into Non-Redemption Agreements with unaffiliated shareholders on June 5, 2026, to reduce redemptions ahead of its proposed business combination with Teamshares Inc. The agreements cover 276,646 non-redeemed Class A ordinary shares in exchange for 37,171 Founder Shares from the Sponsor, with the shareholder meeting scheduled for June 16, 2026. The filing notes no financial results or operational metrics, and does not disclose whether redemptions remain a risk.

• · The extraordinary general meeting is scheduled for June 16, 2026 to vote on the business combination.
• · Non-Redeemed Shares represent Class A ordinary shares (par value $0.0001 per share) held by unaffiliated third-party shareholders.
• · Sponsor will transfer Founder Shares only if NRA Investors do not exercise redemption rights at the meeting.
• · The agreement is intended to reduce the number of public shares redeemed in connection with the closing.
• · Live Oak is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.
• · The Merger Agreement was originally dated November 14, 2025 and may have been further amended.

09-06-2026

VenHub Global, Inc. (VHUB) filed an 8-K on June 9, 2026, disclosing the issuance of an aggregate of 10,670,000 shares of common stock to five independent contractors under one-year service agreements for consulting services in EU/Mediterranean operations, design/architecture, EU market expansion, education sector marketing, and global payments. Additionally, the company will issue 700,000 shares to a third party as part of a settlement agreement. All shares are being issued as restricted securities in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with no general solicitation or advertising used.

• · The company is an emerging growth company as defined under the Securities Act.
• · All shares are issued as restricted securities under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
• · No general solicitation or advertising was used in connection with the issuances.
• · The company's common stock is traded on The Nasdaq Stock Market LLC under the symbol VHUB.

09-06-2026

Pearl Diver Credit Co Inc. filed an 8-K on June 9, 2026, under Item 8.01 (Other Events). The filing is a standard SEC notification with no specific material event disclosed beyond the cover page and XBRL metadata. No financial figures, operational updates, or period-over-period comparisons were provided.

• · Filing type: 8-K, dated June 9, 2026, under Item 8.01 (Other Events).
• · Company incorporated in Delaware, fiscal year end December 31.
• · Securities listed: Common Stock (par value $0.001 per share) and 8.00% Series Preferred Stock due 2029.
• · No amendment flag, no pre-commencement communications, no soliciting material.

09-06-2026

Amaze Holdings, Inc. amended its bylaws to reduce the stockholder quorum requirement from a majority to one-third of shares entitled to vote, effective June 9, 2026. The change was approved by unanimous written consent of the Board of Directors and is intended to facilitate the conduct of business at stockholder meetings. No financial impact or operational changes were disclosed.

• · The amendment reduces the quorum requirement from a majority to one-third of shares entitled to vote.
• · The change was approved via unanimous written consent by the Board of Directors and is effective June 9, 2026.
• · The amendment also clarifies that shares held by the corporation or its majority-owned subsidiaries are not counted for quorum or voting, except when held in a fiduciary capacity.